Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Neurocrine Biosciences (NBIX) EBIT (2016 - 2026)

Neurocrine Biosciences filings provide 16 years of EBIT readings, the most recent being $210.9 million for Q4 2025.

  • On a quarterly basis, EBIT rose 48.52% to $210.9 million in Q4 2025 year-over-year; TTM through Dec 2025 was $619.1 million, a 8.52% increase, with the full-year FY2025 number at $619.1 million, up 8.52% from a year prior.
  • EBIT hit $210.9 million in Q4 2025 for Neurocrine Biosciences, down from $239.0 million in the prior quarter.
  • In the past five years, EBIT ranged from a high of $239.0 million in Q3 2025 to a low of -$114.2 million in Q1 2023.
  • Median EBIT over the past 5 years was $93.6 million (2022), compared with a mean of $89.6 million.
  • Biggest five-year swings in EBIT: soared 384.85% in 2022 and later plummeted 3783.87% in 2023.
  • Neurocrine Biosciences' EBIT stood at -$36.3 million in 2021, then soared by 384.85% to $103.4 million in 2022, then surged by 45.36% to $150.3 million in 2023, then decreased by 5.52% to $142.0 million in 2024, then surged by 48.52% to $210.9 million in 2025.
  • The last three reported values for EBIT were $210.9 million (Q4 2025), $239.0 million (Q3 2025), and $145.6 million (Q2 2025) per Business Quant data.